Bedtime insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type II diabetes

Area of Science:

• Endocrinology
• Metabolic Disorders
• Pharmacology

Background:

• Type 2 diabetes management often requires multifaceted approaches.
• Oral hypoglycemic agents may not achieve adequate glycemic control in all patients.
• Obesity is a common comorbidity in type 2 diabetes, complicating treatment.

Purpose of the Study:

• To assess the efficacy of adding bedtime Neutral Protamine Hagedorn (NPH) insulin to existing sulfonylurea therapy.
• To evaluate this combined treatment in obese patients with type 2 diabetes failing oral agents.
• To determine if this regimen offers a viable alternative to conventional insulin therapy.

Main Methods:

• 16 obese patients with type 2 diabetes, uncontrolled on maximal oral agents, were studied.
• Patients received glipizide or glyburide daily, with dietary education.
• Bedtime NPH insulin was initiated at 0.1-0.2 units/kg and titrated based on fasting blood glucose.

Main Results:

• Mean fasting blood glucose decreased significantly from 13.7 mmol/L to 7.3 mmol/L after 1 year.
• Glycosylated hemoglobin levels dropped from 9.0% to 6.3% within 1 year.
• These improvements indicate enhanced glycemic control with the combined therapy.

Conclusions:

• Adding a nighttime dose of NPH insulin to daytime sulfonylureas is beneficial for obese type 2 diabetics.
• This therapeutic strategy provides a useful alternative for patients whose hyperglycemia persists despite maximal oral therapy.
• The study highlights a practical approach to managing difficult-to-control type 2 diabetes.